U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
BERKELEY, Calif., April 25, 2017 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the following investor conferences in May 2017:
- 42nd Annual Deutsche Bank Health Care Conference in Boston, MA on Wednesday, May 3, 2017 at 8:00 am Eastern Time
- Bank of America Merrill Lynch 2017 Heath Care Conference in Las Vegas, NV on Thursday, May 18, 2017 at 10:00 am Pacific Time
To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 [email protected]
